Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
12 Outubro 2023 - 9:00AM
Business Wire
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene
editing company utilizing its novel proprietary ARCUS® platform to
develop in vivo gene editing therapies for sophisticated gene
edits, including gene insertion, excision, and elimination, today
announced that two abstracts have been accepted by the European
Society of Gene & Cell Therapy (ESGCT) for poster presentations
at the upcoming Congress on October 24-27, 2023, in Brussels,
Belgium.
Presentation Details:
Title: Unique features of ARCUS nucleases enable high
efficiency, targeted gene insertion in vivo Poster Number:
#P641 Presenter: Cassie Gorsuch, VP of Gene Therapy,
Precision Biosciences Date and Time: Wednesday, October 25,
2023, 5:00 PM - 6:15 PM CEST and Thursday, October 26, 2023, 8:30
PM - 9:30 PM CEST Location: Gare Maritime
Title: ARCUS-mediated excision of the “hot spot” region
of the human dystrophin gene results in functional improvement in a
mouse model of Duchenne muscular dystrophy (DMD) Poster
Number: Poster #P653 Presenter: Cassie Gorsuch, VP of
Gene Therapy, Precision Biosciences Date and Time:
Wednesday, October 25, 2023, 5:00 PM - 6:15 PM CEST and Thursday,
October 26, 2023, 8:30 PM - 9:30 PM CEST Location: Gare
Maritime
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is an advanced gene editing company
dedicated to improving life (DTIL) with its novel and proprietary
ARCUS® genome editing platform that differs from other technologies
in the way it cuts, its smaller size, and its simpler structure.
ARCUS is a highly precise and versatile genome editing platform
that was designed with therapeutic safety, delivery, and control in
mind. Using ARCUS, the Company’s pipeline is comprised of in vivo
gene editing candidates designed to deliver lasting cures for the
broadest range of genetic and infectious diseases where no adequate
treatments exist. For more information about Precision BioSciences,
please visit www.precisionbiosciences.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231012210195/en/
Investor and Media Contact: Mei Burris Senior Director of
Finance and Corporate Controller
Mei.Burris@precisionbiosciences.com
Precision BioSciences (NASDAQ:DTIL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Precision BioSciences (NASDAQ:DTIL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
